Instructions for Semaglutide Tablets

1. Generic name: Semaglutide

Product name:Rybelsus

All names: Semaglutide, Semaglutide, Semaglutide

2. Indications:

Semaglutide tablets (Semaglutide) are considered an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Limitations of Use: Semaglutide Tablets have not been studied in patients with a history of pancreatitis. Consider other antidiabetic treatments in patients with a history of pancreatitis. Semaglutide tablets are not suitable for patients with type 1 diabetes.

3. Usage and dosage:

1. Medication management: Patients should take semaglutide tablets at least 30 minutes before the first food, drink or other oral medication of the day, with only no more than 4 ounces of boiled water. Waiting for less than 30 minutes, or taking Semaglutide Tablets with food, drinks (except plain water) or other oral medications will reduce the absorption of Semaglutide Tablets , thus reducing its effects. Waitingmore than 30 minutes to eat may increase the absorption of semaglutide tablets.

2. Recommended dosage: Start taking semaglutide tablets once a day3mg for 30 days. The 3 mg dose is used to initiate treatment and is ineffective for glycemic control; after 30 days on the 3 mg dose, increase the dose to 7 mg once daily; if additional glycemic control is required after at least 30 days on the 7 mg dose, the dose may be increased to 14 mg once daily;

Patients are not advised to take two 7 mg semaglutide tablets to achieve a dose of 14 mg; if a dose is missed, the missed dose should be skipped and the next dose taken the next day.

3. Dose adjustment: Patients receiving daily treatment of 14 mg of Semaglutide tablets can be switched to subcutaneous injection of Semaglutide ( OZEMPIC) at a dose of 0.5 mg once a week. Patients can start subcutaneous injection of Semaglutide on the day after taking the last dose of Semaglutide tablets. There is no equivalent dose of semaglutide tablets1mgsemaglutide injection.

4. Adverse reactions:

The most common adverse reactions of semaglutide tablets are nausea, vomiting, diarrhea and hypoglycemia. After Semaglutide tablets were put on the market, adverse events such as intestinal obstruction, allergic reactions, angioedema, rash, urticaria, cholecystitis, and gallstones (requiring cholecystectomy) have also occurred.

5. Storage:

Semaglutide tablets are stored at 68° to 77°F (20 to 25°C); offset storage is permitted at 59° to 86°F (15° to 30°C) and dispensed in original bottles. Store tablets in original bottle until use to protect tablets from moisture. Store product in a dry place away from moisture.

6. Taboo:

Semaglutide tablets are contraindicated in:

1. Have a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

2. Previous severe hypersensitivity reaction to Semaglutide or any excipient in Semaglutide tablets. Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide tablets.

7. Mechanism of action:

Semaglutide in Semaglutide tablets is a GLP-1 analogue and has 94% sequence homology with human GLP-1. SemaglutideAs a GLP-1 receptor agonist, it selectively binds to and activates the GLP-1 receptor, which is the target of natural GLP-1. GLP-1 is a physiological hormone with multiple effects on glucose mediated by the GLP-1 receptor.

The primary mechanism responsible for the long half-life of semaglutide is albumin binding, which reduces renal clearance and prevents metabolic degradation. In addition, semaglutide is stable and is not degraded by DPP-4 enzyme. Semaglutide lowers blood glucose by stimulating insulin secretion and reducing glucagon secretion, both of which are glucose-dependent. Therefore, when blood sugar is high, insulin secretion is stimulated and glucagon secretion is suppressed. The mechanism of hypoglycemia also involves a slight delay in early postprandial gastric emptying.

8. Special groups:

1. Women of reproductive potential: Due to the long elimination period of semaglutide, it is recommended that women stop taking semaglutide tablets at least 2 months before planning to become pregnant.

2. Breastfeeding: Since breastfed infants may have an unknown potential for serious adverse reactions due to accumulation of SNAC due to breastfeeding, and there are other formulations of semaglutide that can be used during lactation, it is recommended that patients not breastfeed during treatment with semaglutide tablets.